CTRI/2023/03/051121招募中1 期
A Phase-I, multicenter, open-label, dose escalation study of NRC-1111 in adult patients with advanced solid malignancies.
ATCO Pharma Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients will be considered eligible for the study based on the following criteria:
- •1. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements.
- •2. Male or female patients aged 18 years or older at the time of consent.
- •3. Patients must have life expectancy = 8 weeks.
- •4. ECOG Performance Score less than or equal to 2.
- •5. Patients with histologically documented, confirmed diagnosis of an advanced solid
- •malignancy for whom standard treatment options do not exist. Tumours must have
- •progressed (RECIST v1.1) on the last line of therapy before enrolment into the study.
- •6. Patients must have measurable lesion per RECIST v1.1.
- •8. Patients must not have received chemotherapy within 30 days and radiotherapy within
- •3 weeks and must not have undergone surgery within 2 weeks before dosing.
- •9. Patients must be willing to practice birth control during and for 6 months after
- •10. Negative urine pregnancy test within 72 hours before starting study treatment in all premenopausal
- •women (PMS) and woman with < 12 months after onset of menopause.
- •This test is not required for women who have undergone hysterectomy and sterilization.
- •11. Women of childbearing potential, (defined as women physiologically capable of becoming pregnant) they must agree to use effective method of contraception during dosing and for at least 06 months after the treatment discontinuation) practicing
- •two acceptable methods of contraception.
- •12. Male patients must agree to use a condom.
- •Patient is non-fertile (orchiectomy) or has a female partner
- •of nonchildbearing potential (i.e., postmenopausal,
- •surgically sterile).
- •Patient and his female partner must agree to use an
- •adequate contraceptive method throughout the study
- •period and for 6 months following the last dose of
- •investigational product.
- •Male patient engaged in sexual activity with a pregnant
- •female is required to use a condom throughout the study
- •period and for 6 months following the last dose of
- •investigational product.
- •Acceptable methods of contraception include the following:
- •Intrauterine devices plus condoms
- •Double-barrier methods (e.g., condoms and diaphragms with spermicidal gel or foam)
- •Hormonal contraceptives (oral, depot, patch, injectable, or
- •vaginal ring), stabilized for at least 30 days prior to the
- •screening visit, plus condoms. Note: If the patient becomes
- •sexually active during the study, she should use one of the
- •other acceptable methods noted above in addition to the hormonal contraceptive until it has been stabilized for 30 days.
排除标准
- •Patients meeting any of the following criteria will be excluded from the study:
- •1. Has a major illness, including active cardiac, hepatic, endocrine, pulmonary, autoimmune disease, interstitial lung disease, renal or psychiatric disorders, inadequately controlled with therapy corresponding to the illness.
- •2. Patients with brain metastases or primary CNS
- •malignancies. Radiological confirmation is required for symptomatic patients only.
- •3. Patients receiving concurrent therapy for the cancer (Radiation therapy, chemotherapy).
- •4. Has tested positive for HIV, HBsAg, HCV antibody, or HCV RNA at screening. However, patients who test positive for HCV antibody, but negative for HCV RNA, will be allowed. In addition, patients with controlled HIV, chronic HBV on suppressive antiviral therapy, or a history
- •of HCV infection status post-curative antiviral treatment
- •with an HCV viral load below limit of quantification are permitted to participate.
- •5. Has baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 milliseconds [CTCAE Grade 1] using Fredericia’s QT correction formula).
- •6. Patients who are pregnant or lactating.
- •7. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, and which may obscure the evaluation of toxicity or alters drug
- •metabolism.
- •8. Impairment of gastrointestinal function that could significantly alter the absorption of the study drug and also the use of medication altering gastric pH (mild antacids are permitted if taken either 2 hours before or after the study drug administration).
- •9. Prior treatment with mTOR inhibitors in advanced malignancies.
- •10. Patients who received PI3K inhibitor(s) in any stage of their treatment.
- •11. Patients who tested positive for Coronavirus infection (COVID-19) at the time of enrolment.
- •12. Participation in any clinical study within 60 days before the first dose of Investigational Product.
- •13. Patients who are participating in any other clinical trial (both academic and industry run trials).
- •14. Patients with clinically manifest diabetes mellitus (treated and/or with clinical signs or with fasting glucose > 140 mg/dL or 7.8 mmol/L, HbA1c > 5.7), history of gestational diabetes mellitus or documented steroid induced diabetes mellitus.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1, Open-label , Dose EscalationStudy of Berubicin® in Pediatric Patientswith Progressive, Refractory, or Recurrent High GradeGliomasEUCTR2019-004016-58-PLWPD Pharmaceuticals Sp. z o.o.35
尚未招募
1 期
A Phase 1 Study of KK2269 Monotherapy and Combination Therapy with Docetaxel in Adult Participants with Solid Tumors-Part 1: locally advanced or metastatic solid tumors-Part 2: gastric/GEJ/ESO(adeno) or NSCLCJPRN-jRCT2031230419Masegi Chinatsu71
已完成
不适用
A phase I, multicenter, open-label dose escalation and expansion study of LOP628, administered intravenously in adult patients with cKit-positive tumors and acute myeloid leukemiaSmall Cell Lung cancerAcute Myeloide Leukemia10027655GISTNL-OMON42287ovartis15
已完成
不适用
A phase I, multicenter, open-label dose escalation study of LDK378, administered orally in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase(ALK)Tumors with genetic abnormality in ALK10027655NL-OMON36240ovartis4
已完成
不适用
A phase I, open label, multicenter, dose-escalation study of oral HDM201 in adult patients with advanced solid and hematological tumors characterized by wild-type TP53Solid and hematologic tumors1002432410027655NL-OMON46915ovartis24